Venous thromboembolism: current management

Anticoagulation is indicated in most cases of venous thromboembolism Monotherapy with rivaroxaban or apixaban is the preferred option for most adults with acute venous thromboembolism There are no recommended dose reductions for rivaroxaban or apixaban in venous thromboembolism, unlike for atrial fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevens, Hannah, Tran, Huyen, Gibbs, Harry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: NPS MedicineWise 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698234/
https://www.ncbi.nlm.nih.gov/pubmed/31427842
http://dx.doi.org/10.18773/austprescr.2019.039
_version_ 1783444512655278080
author Stevens, Hannah
Tran, Huyen
Gibbs, Harry
author_facet Stevens, Hannah
Tran, Huyen
Gibbs, Harry
author_sort Stevens, Hannah
collection PubMed
description Anticoagulation is indicated in most cases of venous thromboembolism Monotherapy with rivaroxaban or apixaban is the preferred option for most adults with acute venous thromboembolism There are no recommended dose reductions for rivaroxaban or apixaban in venous thromboembolism, unlike for atrial fibrillation The initial duration of anticoagulation is usually three months Extended treatment with low-dose rivaroxaban or apixaban is effective in preventing recurrence in patients with a continuing increased risk of thromboembolism. Both drugs have low rates of major bleeding
format Online
Article
Text
id pubmed-6698234
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher NPS MedicineWise
record_format MEDLINE/PubMed
spelling pubmed-66982342019-08-19 Venous thromboembolism: current management Stevens, Hannah Tran, Huyen Gibbs, Harry Aust Prescr Article Anticoagulation is indicated in most cases of venous thromboembolism Monotherapy with rivaroxaban or apixaban is the preferred option for most adults with acute venous thromboembolism There are no recommended dose reductions for rivaroxaban or apixaban in venous thromboembolism, unlike for atrial fibrillation The initial duration of anticoagulation is usually three months Extended treatment with low-dose rivaroxaban or apixaban is effective in preventing recurrence in patients with a continuing increased risk of thromboembolism. Both drugs have low rates of major bleeding NPS MedicineWise 2019-08-01 2019-08 /pmc/articles/PMC6698234/ /pubmed/31427842 http://dx.doi.org/10.18773/austprescr.2019.039 Text en (c) NPS MedicineWise 2019 http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle Article
Stevens, Hannah
Tran, Huyen
Gibbs, Harry
Venous thromboembolism: current management
title Venous thromboembolism: current management
title_full Venous thromboembolism: current management
title_fullStr Venous thromboembolism: current management
title_full_unstemmed Venous thromboembolism: current management
title_short Venous thromboembolism: current management
title_sort venous thromboembolism: current management
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698234/
https://www.ncbi.nlm.nih.gov/pubmed/31427842
http://dx.doi.org/10.18773/austprescr.2019.039
work_keys_str_mv AT stevenshannah venousthromboembolismcurrentmanagement
AT tranhuyen venousthromboembolismcurrentmanagement
AT gibbsharry venousthromboembolismcurrentmanagement

Ejemplares similares